Roles of RUNX in Hippo pathway signaling

Antonino Passaniti; Jessica L. Brusgard; Yiting Qiao; Marius Sudol; Megan Finch-Edmondson

doi:10.1007/978-981-10-3233-2_26

Roles of RUNX in Hippo pathway signaling

Antonino Passaniti, Jessica L. Brusgard, Yiting Qiao, Marius Sudol, Megan Finch-Edmondson

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

26 Scopus citations

Abstract

The Runt-domain (RD) transcription factors (RUNX genes) are an important family of transcriptional mediators that interact with a variety of proteins including the Hippo pathway effector proteins, YAP and TAZ. In this chapter we focus on two examples of RUNX-TAZ/YAP interactions that have particular significance in human cancer. Specifically, recent evidence has found that RUNX2 cooperates with TAZ to promote epithelial to mesenchymal transition mediated by the soluble N-terminal ectodomain of E-Cadherin, sE-Cad. Contrastingly, in gastric cancer, RUNX3 acts as a tumor suppressor via inhibition of the YAP-TEAD complex and disruption of downstream YAP-mediated gene transcription and the oncogenic phenotype. The reports highlighted in this chapter add to the growing repertoire of instances of Hippo pathway crosstalk that have been identified in cancer. Elucidation of these increasingly complex interactions may help to identify novel strategies to target Hippo pathway dysregulation in human cancer.

Original language	English
Title of host publication	Advances in Experimental Medicine and Biology
Publisher	Springer New York LLC
Pages	435-448
Number of pages	14
DOIs	https://doi.org/10.1007/978-981-10-3233-2_26
State	Published - 2017
Externally published	Yes

Publication series

Name	Advances in Experimental Medicine and Biology
Volume	962
ISSN (Print)	0065-2598
ISSN (Electronic)	2214-8019

Keywords

Breast cancer
Gastric cancer
Hippo pathway
RUNX proteins
TAZ
TEAD
YAP
sE-Cad

Access to Document

10.1007/978-981-10-3233-2_26

Cite this

@inbook{d2667586cdab424fa6d5a8c6f6b125e0,

title = "Roles of RUNX in Hippo pathway signaling",

abstract = "The Runt-domain (RD) transcription factors (RUNX genes) are an important family of transcriptional mediators that interact with a variety of proteins including the Hippo pathway effector proteins, YAP and TAZ. In this chapter we focus on two examples of RUNX-TAZ/YAP interactions that have particular significance in human cancer. Specifically, recent evidence has found that RUNX2 cooperates with TAZ to promote epithelial to mesenchymal transition mediated by the soluble N-terminal ectodomain of E-Cadherin, sE-Cad. Contrastingly, in gastric cancer, RUNX3 acts as a tumor suppressor via inhibition of the YAP-TEAD complex and disruption of downstream YAP-mediated gene transcription and the oncogenic phenotype. The reports highlighted in this chapter add to the growing repertoire of instances of Hippo pathway crosstalk that have been identified in cancer. Elucidation of these increasingly complex interactions may help to identify novel strategies to target Hippo pathway dysregulation in human cancer.",

keywords = "Breast cancer, Gastric cancer, Hippo pathway, RUNX proteins, TAZ, TEAD, YAP, sE-Cad",

author = "Antonino Passaniti and Brusgard, {Jessica L.} and Yiting Qiao and Marius Sudol and Megan Finch-Edmondson",

note = "Funding Information: The research of MS, YQ, and MFE has been supported by generous “Seed Grants” from NUS-MBI-IMCB-A*STAR of the Republic of Singapore. AP was supported by a VA Health Services Research & Development award and a Pilot Grant project from the Marlene & Stewart Greenebaum Cancer Center. The authors would also like to acknowledge the assistance of Chun Xi Wong in preparation of the figure illustrations. Publisher Copyright: {\textcopyright} Springer Nature Singapore Pte Ltd. 2017.",

year = "2017",

doi = "10.1007/978-981-10-3233-2_26",

language = "English",

series = "Advances in Experimental Medicine and Biology",

publisher = "Springer New York LLC",

pages = "435--448",

booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Roles of RUNX in Hippo pathway signaling

AU - Passaniti, Antonino

AU - Brusgard, Jessica L.

AU - Qiao, Yiting

AU - Sudol, Marius

AU - Finch-Edmondson, Megan

N1 - Funding Information: The research of MS, YQ, and MFE has been supported by generous “Seed Grants” from NUS-MBI-IMCB-A*STAR of the Republic of Singapore. AP was supported by a VA Health Services Research & Development award and a Pilot Grant project from the Marlene & Stewart Greenebaum Cancer Center. The authors would also like to acknowledge the assistance of Chun Xi Wong in preparation of the figure illustrations. Publisher Copyright: © Springer Nature Singapore Pte Ltd. 2017.

PY - 2017

Y1 - 2017

N2 - The Runt-domain (RD) transcription factors (RUNX genes) are an important family of transcriptional mediators that interact with a variety of proteins including the Hippo pathway effector proteins, YAP and TAZ. In this chapter we focus on two examples of RUNX-TAZ/YAP interactions that have particular significance in human cancer. Specifically, recent evidence has found that RUNX2 cooperates with TAZ to promote epithelial to mesenchymal transition mediated by the soluble N-terminal ectodomain of E-Cadherin, sE-Cad. Contrastingly, in gastric cancer, RUNX3 acts as a tumor suppressor via inhibition of the YAP-TEAD complex and disruption of downstream YAP-mediated gene transcription and the oncogenic phenotype. The reports highlighted in this chapter add to the growing repertoire of instances of Hippo pathway crosstalk that have been identified in cancer. Elucidation of these increasingly complex interactions may help to identify novel strategies to target Hippo pathway dysregulation in human cancer.

AB - The Runt-domain (RD) transcription factors (RUNX genes) are an important family of transcriptional mediators that interact with a variety of proteins including the Hippo pathway effector proteins, YAP and TAZ. In this chapter we focus on two examples of RUNX-TAZ/YAP interactions that have particular significance in human cancer. Specifically, recent evidence has found that RUNX2 cooperates with TAZ to promote epithelial to mesenchymal transition mediated by the soluble N-terminal ectodomain of E-Cadherin, sE-Cad. Contrastingly, in gastric cancer, RUNX3 acts as a tumor suppressor via inhibition of the YAP-TEAD complex and disruption of downstream YAP-mediated gene transcription and the oncogenic phenotype. The reports highlighted in this chapter add to the growing repertoire of instances of Hippo pathway crosstalk that have been identified in cancer. Elucidation of these increasingly complex interactions may help to identify novel strategies to target Hippo pathway dysregulation in human cancer.

KW - Breast cancer

KW - Gastric cancer

KW - Hippo pathway

KW - RUNX proteins

KW - TAZ

KW - TEAD

KW - YAP

KW - sE-Cad

UR - http://www.scopus.com/inward/record.url?scp=85015450567&partnerID=8YFLogxK

U2 - 10.1007/978-981-10-3233-2_26

DO - 10.1007/978-981-10-3233-2_26

M3 - Chapter

C2 - 28299672

AN - SCOPUS:85015450567

T3 - Advances in Experimental Medicine and Biology

SP - 435

EP - 448

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -

Roles of RUNX in Hippo pathway signaling

Abstract

Publication series

Keywords

Access to Document

Fingerprint

Cite this